Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:33 15/01/2026 GMT			5-day change	1st Jan Change
114.48 ^CHF	-1.36%		+0.63%	+4.45%

04:37pm	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01:23pm	NOVARTIS AG : Barclays remains Neutral	ZD

Relation announces collaboration with Novartis on atopic diseases

Published on 12/09/2025 at 08:06 am GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

04:37pm	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01:23pm	NOVARTIS AG : Barclays remains Neutral	ZD
01-14	Dr. Reddy's Laboratories Launches Olopatadine Hydrochloride Ophthalmic Solution in US	MT
01-14	SciNeuro Grants Novartis Rights for Alzheimer's Disease Drug	MT
01-14	Swiss stocks - Factors to watch on January 14	RE
01-13	Travere shares fall as US FDA extends review of rare kidney disease drug	RE
01-13	Novartis eyes more bolt-on acquisitions, CEO says	RE
01-13	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-13	Swiss stocks - Factors to watch on January 13	RE
01-13	Novartis Saudi Partners with Saudi Scientific Organization on Chronic Urticaria Awareness Campaign	MT
01-12	Novartis AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM
01-12	Novartis eyes more bolt-on acquisitions, CEO says	RE
01-12	Swiss Market Index Begins Week Flat; UBS, Novartis Edge Lower	MT
01-12	Novartis to Do Value-Creating Bolt-Ons	CI
01-12	SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs	RE
01-12	Kyverna Therapeutics, Inc. Appoints Christi Shaw as Executive Chairperson of the Board, Effective January 12, 2026	CI
01-09	Novartis to Develop New US Radioligand Therapy Manufacturing Site in Florida	MT
01-09	Novartis to Build RLT Manufacturing Facility in Florida	MT
01-09	Novartis to Build Radioligand Therapy Facility in Florida	DJ
01-09	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida	RE
01-09	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	DJ
01-09	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	DJ
01-09	Novartis to Add Radioligand Therapy Manufacturing Facility in Winter Park, Florida, Fourth in US to Serve Patients and Advance $23 Billion Investment	CI
01-09	Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices	DJ
01-08	Tango Therapeutics, Inc. Announces Board and Executive Changes	CI

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

02-03 - Q4 2025 Earnings Release

More about the company